Assessment of maximum tolerated dose of a new herbal drug, Semelil (ANGIPARS™) in patients with diabetic foot ulcer: A Phase I clinical trial

Daru

Volumn 16, Issue SUPPL. 1, 2008, Pages 25-30

  Heshmat, R ^a,b   Mohammad, K ^a   Mohajeri Tehrani, M R ^b   Tabatabaie Malazy, O ^b   Keshtkar, A A ^c   Gharibdoust, F ^a   Larijani, B ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Golsetan University of Medical Sciences   (Iran)

Author keywords

ANGIPARS ; Clinical trial phase I; Diabetic foot ulcer; Melilotus officinalis; Semelil; Wound healing

Indexed keywords

AMYLASE; ANGIPARS; HEMOGLOBIN A1C; HERBACEOUS AGENT; POTASSIUM; SEMELIL; SODIUM; UNCLASSIFIED DRUG;

ADULT; AGED; AMYLASE BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE MEASUREMENT; BODY TEMPERATURE MEASUREMENT; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC FOOT; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; HEMATURIA; HUMAN; INJECTION SITE PHLEBITIS; LIVER FUNCTION TEST; MALE; MAXIMUM TOLERATED DOSE; PATIENT ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PROTEINURIA; TREATMENT OUTCOME; WOUND CARE;

EID: 38949124399     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Zimmet PZ. Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia 1999; 42: 499-518.
2. Abbott CA, Vileikyte L, Williamson S, Carrington A.L, Boulton A.IM. Multi-center study of the incidence and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998; 21:1071-5.
3. Fryberg RG, Armstrong DG, Giurini J, Edwards A, kravatte M, kravitz S. Diabetic Foot Disorders, A Clinical Practice Guideline. American college of Foot and Ankle Surgeons and the American college of foot and Ankle Orthopedics and Medicine 2000: 1-48.
4. Khatib O. Epidemiology of Diabetic Foot. International seminar on Diabetic Foot Nov.15-17, 2007, Tehran, Iran, p: 15.
5. Reiber GE, Vileikyte L, Boyko EJ, Del Aguila M, Smith DG, Lavery LA, Boulton A.IM. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22:157-162.
6. Gibbons GW, Eliopoulos GM. Infection of the diabetic foot. In: Management of Diabetic Foot Problems, p.121, edited by GP Kozak, DR Campbell, RG Frykberg, and GM Habershaw. WB Saunders, Philadelphia, 1995.
7. Levin ME. Foot lesions in patients with diabetes mellitus. Endocrin Metab Clin North Am 1996; 25: 447-62.
8. Levin ME. Foot lesions in patients with diabetes mellitus. Endocrine Metab Clin North Am 1996; 25:447-62.
9. U.S. Department of Health and Human Services. Diabetes Surveillance , 1997. Centers for Disease Control and Prevention, Atlanta, GA, 1997.
10. Larijani B, Bastanhagh MH, Pajouhi M, Afshari M, Khani M, Shajarian M. Lower limb amputation rate in patients with type 2 diabetes managed at the Imam Khomeini and Doctor Shariati Hospitals between 1979 and 1994.IJDL 2002;1(1):83-5.persian
11. Larsson J, Agardh CD, Apelqvist J, Stenstrom A. Long term prognosis after healed amputation in patients with diabetes. Clin Orthop 1998; 350:149-158.
12. Spollett CR. Preventing amputations in diabetic populations. Nursing Clinics of North America 1998; 33: 629-41.
13. Armstrong DG, Horkless LB. Outcomes of preventive care in diabetic foot specialty clinic. J Foot Ankle Surg1998; 37: 460-6.
14. American Diabetes Association. Consensus development conference on diabetic foot wound care. Diabetes Care 1999; 22:1354-60.
15. Steed DL, Donohoe D, Webster MW, Lindsley L. Diabetic Ulcer Study Group. Effect of extensive debridement and treatment on the healing of DFUs. J Am CoIl Surg 1996;183:61-4.
16. Caravaggi C, Faglia E, De Giglio R. Effectiveness and safety of a non-removable fiberglass offbearing cast versus a therapeutic shoe in the treatment of neuropathic foot ulcers: a randomized study. Diab Care 2000; 23: 1746-51.
17. Armstrong DG, Nguyen HC, Lavery LA, et al. Off-loading the diabetic foot wound. Diab Care 2001; 24: 1019-22.
18. Canter KG. Conservative management of wounds. Ciln Podiatr Med Surg 1991; 8:787.
19. Steed DL. Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasco Surg 1995, 21:71-81.
20. Wieman TJ, Smiell JM, Yachin Su. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (Becaplermin) in patients with chronic neuropathic diabetic ulcers. a phase III randomized p1acebo-controlled double-blind study. Diabetes Care 1998; 21:822-7.
21. Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Prendergast JJ, Ricotta JJ, Steed DP, Lipkin SL. Use of Dermagraft, a cultured human dermis, to treat DFUs. Diabetes Care 1996; 19:350-4.
22. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of DFUs. Artificial Organs 1997; 21:1203-10.
23. Eaglestein WH, Falanga V. Tissue engineering and the development of Apligraf, a human skin equivalent. Adv. Wound Care 1998; 11(Suppl. 1):1-8.
24. Faglia E, Favales F, Aldeghi A., Calia P, Quarantiello A., Criani G, Michael M, Campagnoli P, Morabito A. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic DFU: a randomized study. Diabetes Care 1996; 19:1338-343.
25. Brakora, M.J., Sheffield, P.J. Hyperbaric oxygen therapy for diabetic wounds. Clin Podiatr Med Surg 1995; 12:105-17.
26. Argenta L, Morykwas MJ. Vacuum-assisted closure. A new treatment method for wound control and treatment. clinical experience. Ann Plast Surg 1997; 38:563-76.
27. Hogge J, Krasner D, Nguyen H, Harkless LB, Armstrong DG. The potential benefits of advanced therapeutic modalities in the treatment of diabetic foot wounds. J Am Pediatr Med Assoc 2000; 90:57-65.
28. Larijani B, Hasani Ranjbar S. Overview of diabetic foot; novel treatments in diabetic foot ulcer. DARU 2008; 16(suppl.1): 1-6.
29. Abdollahi M, Farzamfar B, Salary P, Khorram Khorshid HR, Larijani B, Farhadi M, Madani SH. Rodent acute and sub-chronic toxicity evaluation of Semelil (ANGIPARS™), a new phytotherapeutic drug for wound healing. DARU 2008; 16(suppl.1): 7-14.
30. Farzamfar B, Abdollahi M, Ka'abinejadian S, Heshmat R, Shahhosseiny MH, Novitsky Y.A, Farhadi M. Sub-chronic toxicity study of a novel herbal-based formulation (Semelil) on dogs. DARU 2008; 16(suppl.1): 15-19.
31. Khorram Khorshid HR, Sadeghi B, Heshmat R, Abdollahi M, Salary P, Farzamfar B, Madani SH. In vivo and in vitro genotoxicity studies of Semelil (ANGIPARS™). DARU 2008; 16(suppl.1): 20-24.
32. nd ed., 2004. chap6. p.215-238.
33. Ivanova A. A new Dose-Finding Design for Bivariate Outcomes. Biometrics 2003; 59, 1001-7.
34. Rosenberger WF, Haines LM. Competing designs for phase I clinical trials: a review. Statist Med 2002; 21:2757-70.
35. O' Quigley J. Continual reassessment method. In Handbook of Statistics in Clinical Oncology, Crowley (ed.).Marcel Dekker: New York, 2001; 35-72.
36. Common toxicity criteria manual, version 2.0, June 1, 1999, NCI CTEP Help Desk.
37. WHO (World Health Organization) Toxicity Criteria by Grade that is available in http://www.fda.gov/cder/cancer/toxicityframe.htm.